BioArctic announces that the European Patent Office (EPO) has decided to grant a European patent (EP2539366) to BioArctic AB and the patent will be published on November 08, 2017.
The European patent EP2539366 covers the monoclonal antibody candidate BAN0805 per se, intended for treatment of neurodegenerative disorders, including Parkinson’s disease. Validated national patents will expire on February 25, 2031 and patent term extensions will be available for up to five years after marketing authorizations have been approved. Corresponding patents are also granted in major markets including US, Japan and China.
Photo of Gunilla Osswald, CEO of BioArctic